“…3 They are especially so in the pharmaceutical arena. 4 Metastable polymorphs can often be recrystallized in a small-scale through swift cooling 5 and rapid solvent evaporation 6 by suddenly raising the relative supersaturation, S, 7 and/or broadening of the metastable zone width (MZW), 8 or through the solvent effect 9 by altering the shape of the solubility curve and MZW, 10 or through heterogeneous nucleation 11 by lowering the interfacial energy and/or S. 12 However, unlike biological environments where a bulk material with a metastable modification can be cleverly induced, confined, and stabilized through the layering and tiling of the organic nucleation templates and nanosized crystals of metastable polymorph, 13 large-scale crystal production of metastable polymorph for industrial applications is more difficult to achieve because of the interplay among the four key factors: (1) the time delay in temperature change over the large heat capacity of the solution volume in a vessel even with a good mixing which, in turn, can affect the temperature-dependent equilibrium saturation concentration, C*, and the initial S 0 = C 0 /C*, where C 0 is the initial concentration, (2) the Ostwald's rule of stages 14 that metastable polymorphs are prone to be formed and then transformed rapidly into only one thermodynamically stable polymorph, (3) the nucleation of thermodynamically stable polymorph when S at later times is lower than the initial S 0 , and (4) instead of going through recrystallization, realistically, the process usually undergoes crystallization immediately after a chemical reaction.…”